Apollomics Inc (APLM)

$0.16

-0.01

(-3.66%)

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $0.16
    $0.16
    $0.16
    downward going graph

    2.75%

    Downside

    Day's Volatility :5.46%

    Upside

    2.79%

    downward going graph
  • $0.11
    $2.90
    $0.16
    downward going graph

    34.19%

    Downside

    52 Weeks Volatility :96.37%

    Upside

    94.48%

    downward going graph

Returns

PeriodApollomics IncIndex (Russel 2000)
3 Months
-17.28%
0.0%
6 Months
-71.79%
0.0%
1 Year
-93.97%
0.0%
3 Years
-99.46%
-21.4%

Highlights

Market Capitalization
17.4M
Book Value
$0.19
Earnings Per Share (EPS)
-0.15
Wall Street Target Price
2.0
Profit Margin
0.0%
Operating Margin TTM
-1431.62%
Return On Assets TTM
-62.74%
Return On Equity TTM
-149.31%
Revenue TTM
2.1M
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
262.3%
Gross Profit TTM
0.0
EBITDA
-53.1M
Diluted Eps TTM
-0.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-0.65
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Apollomics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1150.0%

Current $0.16
Target $2.00

Technicals Summary

Sell

Neutral

Buy

Apollomics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Apollomics Inc
Apollomics Inc
15.84%
-71.79%
-93.97%
-99.46%
-99.46%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.53%
7.92%
21.76%
83.48%
256.87%
Novo Nordisk A/s
Novo Nordisk A/s
-12.73%
-9.68%
25.05%
134.03%
343.37%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.47%
71.74%
59.21%
32.07%
248.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.35%
12.64%
28.18%
152.92%
164.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Apollomics Inc
Apollomics Inc
NA
NA
NA
0.0
-1.49
-0.63
NA
0.19
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Apollomics Inc
Apollomics Inc
Buy
$17.4M
-99.46%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
256.87%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
343.37%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.4B
248.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
164.64%
32.84
-4.74%

Insights on Apollomics Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 146.1%

Company Information

formerly known as cbt pharmaceuticals. at apollomics, we are a purpose driven company imagining a world without cancer. we let science drive our decision making to advance our programs. we believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve. apollomics is committed to the discovery and development of oncology combination therapies. we believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. we have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. when developing an asset, we begin with rigorous ind-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. this path may be as a monotherapy, a combination therapy, or both. while our ultimate goal is to study each of our assets in combination with other agents, we h

Organization
Apollomics Inc
Employees
45
CEO
Dr. Guo-Liang Yu Ph.D.
Industry
Miscellaneous

FAQs